FDA Approved: IMCIVREE — Supplemental Application (Rhythm Pharmaceuticals, Inc)

View source ↗

Summary

The FDA approved a supplemental application for IMCIVREE (setmelanotide) filed by Rhythm Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity Due to Lepr Deficiency
• Obesity Due to Pcsk1 Deficiency
• Obesity Due to Pomc Deficiency

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

SUPPL AP for IMCIVREE (SETMELANOTIDE)